School of Public Health

Stehman-Breen, Catherine

Catherine Stehman-Breen

Affiliate Associate Professor, Epidemiology

Vice President, Clinical Development

Education

MD Medicine, University of Chicago, 1990
MS Epidemiology, University of Washington, 1996
BS Biology, Colby College, 1985

Contact Info

51 Gray St
Boston, MA 02116
Tel: 805-890-4210
stehman@mac.com

My academic career focuses on clinical research in bone, kidney and neurologic diseases. The goal of these clinical trial programs is to bring innovative therapeutics to people with serious illnesses. My areas of focus are osteoporosis, hyperparathyroidism in kidney disease and migraine.

My academic career focuses on clinical research in bone, kidney and neurologic diseases. The goal of these clinical trial programs is to bring innovative therapeutics to people with serious illnesses. My areas of focus are osteoporosis, hyperparathyroidism in kidney disease and migraine.

Catherine received her medical degree from University of Chicago in 1990. She completed her residency and fellowship training at the University of Washington where she also received a Masters of Science degree in Epidemiology. She spent six years as a Faculty member in the Division of Nephrology at University of Washington. Her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine joined Amgen in 2003 where she became the Global Development Leader for Aranesp and Epogen. She became the Therapeutic Area Head for Bone, Nephrology and Neuroscience and was responsible for clinical programs related to bone loss, nephrology and several neuroscience indications. In 2015, she became the therapeutic area head for pain at Regeneron Pharmaceuticals. She is now the head of Clinical Operations.

Projects

• Fasinumab: A monoclonal antibody to nerve growth factor and a potential treatment for chronic pain

Research Interests

• Fasinumab: A monoclonal antibody to nerve growth factor and a potential treatment for chronic pain

The epidemiology of bone disease in patients with Duchenne muscular dystrophy.